PharmaCyte Biotech (PMCB) Liabilities and Shareholders Equity (2011 - 2026)
PharmaCyte Biotech (PMCB) posted Liabilities and Shareholders Equity of $36.71 million for fiscal Q1 2027 (quarter ended Jul 31, 2026), down 18.6% from $45.11 million a year earlier and down 21.5% from the prior quarter.
Powered by 
Analysis
PharmaCyte Biotech (PMCB) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
At the end of FY2026 (ended Apr 30, 2026), PharmaCyte Biotech's Liabilities and Shareholders Equity came in at $46.75 million, down 15.3% from FY2025.
- Annual Liabilities and Shareholders Equity has declined for four consecutive fiscal years, though with a five-year compound annual growth rate of 44.6% (FY2021 to FY2026).
- In prior fiscal years, PharmaCyte Biotech's Liabilities and Shareholders Equity was $55.17 million in FY2025 (-7.9%), $59.9 million in FY2024 (-18.3%), $73.28 million in FY2023 (-19.1%) and $90.62 million in FY2022.
- The fiscal Q1 2027 figure stands as the lowest quarterly Liabilities and Shareholders Equity since fiscal Q1 2022.
- On a year-over-year basis, Liabilities and Shareholders Equity increased in two of the last eight quarters, with an average decline of 14.6%.
- The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was fiscal Q2 2022, with growth of 932.4%; the weakest was fiscal Q3 2025, with a decline of 38.6%.
- According to Business Quant data, Liabilities and Shareholders Equity for the three prior fiscal quarters was $46.75 million (Q4 2026), $55.87 million (Q3 2026) and $55.98 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | PharmaCyte Biotech | 4.40 Mn | 4.40 Mn | - | 36.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 36.71 Mn |
| Apr 30, 2026 | 46.75 Mn |
| Jan 31, 2026 | 55.87 Mn |
| Oct 31, 2025 | 55.98 Mn |
| Jul 31, 2025 | 45.11 Mn |
| Apr 30, 2025 | 55.17 Mn |
| Jan 31, 2025 | 43.83 Mn |
| Oct 31, 2024 | 55.10 Mn |
| Jul 31, 2024 | 70.19 Mn |
| Apr 30, 2024 | 59.90 Mn |
| Jan 31, 2024 | 71.36 Mn |
| Oct 31, 2023 | 78.88 Mn |
| Jul 31, 2023 | 79.88 Mn |
| Apr 30, 2023 | 73.28 Mn |
| Jan 31, 2023 | 77.95 Mn |
| Oct 31, 2022 | 82.35 Mn |
| Jul 31, 2022 | 87.39 Mn |
| Apr 30, 2022 | 90.62 Mn |
| Jan 31, 2022 | 91.94 Mn |
| Oct 31, 2021 | 92.31 Mn |
API Access
PharmaCyte Biotech Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=PMCB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "PMCB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=PMCB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();